Stockholm, April 30, 2020: A multifaceted, scientific study published today in the peer-reviewed journal Advanced Healthcare Materials shows that a radical new approach using mesoporous silica particles (MSPs) can be used to prevent type 2-diabetes and treat obesity. By blocking food enzyme activity, MSPs reduce energy intake from food and lower blood sugar and other metabolic risk factors. The MSPs are administered orally in solution and passed harmlessly from the body in stools.

The study report comprising a combination of clinical, ex vivo, in vitro and in vivo data:

 1) confirms previously reported reductions in glycated hemoglobin (HbA1c) and LDL cholesterol in man in response to MSP ingestion,

 2) demonstrates sequestration of pancreatic amylase and lipase in a MSP pore-size dependent manner

 3) describes in ex vivo experiments in conditions mimicking intestinal conditions and in vivo experiments in mice, enzyme activities dropped upon exposure to the engineered MSP.

Taken together, the results are compatible with a mode of action whereby a portion of the enzymes are trapped inside the MSPs resulting in an enzyme-blocking effect.

The head of the research team behind the study, Professor Tore Bengtsson at the Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University comments: “To get a deeper understanding of the conditions under which MSPs can trap enzymes of interest, we designed a range of experiments including studies in obese individuals, ex vivo, in vitro and in vivo experiments in mice. The results fully support our original concept of using MSPs as “molecular sieves” to prevent type 2-diabetes and treat obesity.”

For more information, please contact:

Tore Bengtsson, Professor at the Department of Molecular Biosciences, Stockholm University

Phone +46 70 5473994,



Title and link to the scientific publication:

Entrapping Digestive Enzymes with Engineered Mesoporous Silica Particles Reduces Metabolic Risk Factors in Humans, Advanced Healthcare Materials, 2020.